PMID- 32097659
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 875
DP  - 2020 May 15
TI  - Thromboxane A(2) in the paraventricular hypothalamic nucleus mediates 
      glucoprivation-induced adrenomedullary outflow.
PG  - 173034
LID - S0014-2999(20)30126-6 [pii]
LID - 10.1016/j.ejphar.2020.173034 [doi]
AB  - Glucoprivation stimulates a rapid sympathetic response to release and/or secrete 
      catecholamines into the bloodstream. However, the central regulatory mechanisms 
      involving adrenoceptors and prostanoids production in the paraventricular 
      hypothalamic nucleus (PVN) that are responsible for the glucoprivation-induced 
      elevation of plasma catecholamines are still unresolved. In this study, we aimed 
      to clarify whether glucoprivation-induced activation of noradrenergic neurons 
      projecting to the PVN can induce alpha- and/or beta-adrenergic receptor activation and 
      prostanoids production in the PVN to elevate plasma catecholamine levels. We 
      examined the effects of alpha- and beta-adrenergic receptor antagonists, a 
      cyclooxygenase inhibitor, a thromboxane A synthase inhibitor, and a PGE(2) 
      subtype EP(3) receptor antagonist on intravenously administered 2-deoxy-D-glucose 
      (2-DG)-induced elevation of noradrenaline in the PVN and plasma levels of 
      catecholamine in freely moving rats. In addition, we examined whether 
      intravenously administered 2-DG can increase prostanoids levels in the PVN 
      microdialysates. Intracerebroventricular (i.c.v.) pretreatment with phentolamine 
      (a non-selective alpha-adrenergic receptor antagonist) suppressed the 2-DG-induced 
      increase in the plasma level of adrenaline, whereas i.c.v. pretreatment with 
      propranolol (a non-selective beta-adrenergic receptor antagonist) suppressed the 
      2-DG-induced elevation of the plasma level of noradrenaline. I.c.v. pretreatment 
      with indomethacin (a cyclooxygenase inhibitor) and furegrelate (a thromboxane 
      synthase inhibitor) attenuated the 2-DG-induced elevations of both noradrenaline 
      and adrenaline levels. Furthermore, 2-DG administration elevated the thromboxane 
      B(2) level, a metabolite of thromboxane A(2) in PVN microdialysates. Our results 
      suggest that glucoprivation-induced activation of alpha- and beta-adrenergic receptor in 
      the brain including the PVN and then thromboxane A(2) production in the PVN, 
      which are essential for the 2-DG-induced elevations of both plasma adrenaline and 
      noradrenaline levels.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Tachi, Masahiko
AU  - Tachi M
AD  - Aichi Prefectural Institute of Public Health, Japan.
FAU - Yamaguchi, Naoko
AU  - Yamaguchi N
AD  - Department of Pharmacology, Aichi Medical University School of Medicine, Japan.
FAU - Okada, Shoshiro
AU  - Okada S
AD  - Department of Pharmacology, Aichi Medical University School of Medicine, Japan. 
      Electronic address: okadas@aichi-med-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20200222
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Benzofurans)
RN  - 0 (Blood Glucose)
RN  - 0 (Receptors, Adrenergic, alpha)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 57576-52-0 (Thromboxane A2)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - KX4D9BZA6X (furegrelate)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - XXE1CET956 (Indomethacin)
RN  - YKH834O4BH (Epinephrine)
RN  - Z468598HBV (Phentolamine)
SB  - IM
MH  - Adrenal Medulla/*metabolism
MH  - Animals
MH  - Benzofurans/administration & dosage
MH  - Blood Glucose/*metabolism
MH  - Deoxyglucose/administration & dosage
MH  - Epinephrine/blood/metabolism
MH  - Indomethacin/administration & dosage
MH  - Injections, Intraventricular
MH  - Male
MH  - Neurons/metabolism
MH  - Norepinephrine/blood/metabolism
MH  - Paraventricular Hypothalamic Nucleus/drug effects/*metabolism
MH  - Phentolamine/administration & dosage
MH  - Rats
MH  - Receptors, Adrenergic, alpha/metabolism
MH  - Receptors, Adrenergic, beta/metabolism
MH  - Thromboxane A2/*metabolism
OTO - NOTNLM
OT  - 2-Deoxy-D-glucose
OT  - Adrenergic receptor
OT  - Paraventricular hypothalamic nucleus
OT  - Plasma catecholamine
OT  - Thromboxane A(2)
COIS- Declaration of competing interest None.
EDAT- 2020/02/26 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/02/26 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/02/20 00:00 [revised]
PHST- 2020/02/21 00:00 [accepted]
PHST- 2020/02/26 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/02/26 06:00 [entrez]
AID - S0014-2999(20)30126-6 [pii]
AID - 10.1016/j.ejphar.2020.173034 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2020 May 15;875:173034. doi: 10.1016/j.ejphar.2020.173034. Epub 
      2020 Feb 22.